Skip to main navigation
Skip to content
InMed-logo-01

    Pharmaceutical Programs

  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu

    Pharmaceutical Programs

  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Rare Cannabinoid Manufacturing

  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ - Cannabinoid Manufacturing
    • Baymedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • IR Nav

  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About

  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn

  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Subscribe
NASDAQ_Logo

Press Releases

Press Releases

Jan 10, 2023
InMed Provides Business Update and Milestones for 2023
Dec 15, 2022
InMed Announces Results of 2022 Annual General Meeting
Dec 12, 2022
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
Nov 21, 2022
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
Nov 18, 2022
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
Nov 17, 2022
InMed Provides Update on Management Changes
Nov 16, 2022
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
Nov 11, 2022
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
Nov 10, 2022
Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022
Oct 26, 2022
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 227

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical Programs

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

Rare Cannabinoid Manufacturing

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ - Cannabinoid Manufacturing
  • Baymedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

IR Nav

Investor

  • News Releases
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

About

Corporate

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabis Treatments for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Legal Nav

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer

Social icons

  • Find Us On:
  • >
  • >
  • >